Nazzareno Galie

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9226784/publications.pdf

Version: 2024-02-01

255	66,806	3325	677
papers	citations	91 h-index	254 g-index

285	285	285	30235
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal, 2016, 37, 67-119.	1.0	5,074
2	Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal, 2009, 30, 2493-2537.	1.0	3,108
3	Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal, 2008, 29, 2276-2315.	1.0	2,645
4	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal, 2014, 35, 3033-3080.	1.0	2,591
5	Bosentan Therapy for Pulmonary Arterial Hypertension. New England Journal of Medicine, 2002, 346, 896-903.	13.9	2,545
6	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal, 2020, 41, 543-603.	1.0	2,426
7	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Respiratory Journal, 2015, 46, 903-975.	3.1	2,415
8	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal, 2018, 39, 213-260.	1.0	2,246
9	Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. New England Journal of Medicine, 2005, 353, 2148-2157.	13.9	2,237
10	ESC Guidelines for the management of grown-up congenital heart disease (new version 2010): The Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC). European Heart Journal, 2010, 31, 2915-2957.	1.0	2,134
11	Inhaled Iloprost for Severe Pulmonary Hypertension. New England Journal of Medicine, 2002, 347, 322-329.	13.9	1,626
12	Clinical classification of pulmonary hypertension. Journal of the American College of Cardiology, 2004, 43, S5-S12.	1.2	1,542
13	Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 800-804.	2.5	1,288
14	Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism. New England Journal of Medicine, 2014, 370, 1402-1411.	13.9	1,221
15	Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 809-818.	13.9	1,168
16	Guidelines for the diagnosis and treatment of pulmonary hypertension. European Respiratory Journal, 2009, 34, 1219-1263.	3.1	1,127
17	Riociguat for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 330-340.	13.9	1,120
18	Ambrisentan for the Treatment of Pulmonary Arterial Hypertension. Circulation, 2008, 117, 3010-3019.	1.6	967

#	Article	IF	Citations
19	Tadalafil Therapy for Pulmonary Arterial Hypertension. Circulation, 2009, 119, 2894-2903.	1.6	956
20	Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. New England Journal of Medicine, 2015, 373, 834-844.	13.9	906
21	Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. European Heart Journal, 2004, 25, 2243-2278.	1.0	903
22	Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY) Tj ETQq0 0 0 rgBT /Overlock 10	6.3	844
23	Selexipag for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2015, 373, 2522-2533.	13.9	790
24	Bosentan Therapy in Patients With Eisenmenger Syndrome. Circulation, 2006, 114, 48-54.	1.6	773
25	Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. European Heart Journal, 2020, 41, 2083-2088.	1.0	716
26	Clinical and Molecular Genetic Features of Pulmonary Hypertension in Patients with Hereditary Hemorrhagic Telangiectasia. New England Journal of Medicine, 2001, 345, 325-334.	13.9	676
27	Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 297, L1013-L1032.	1.3	645
28	Risk stratification and medical therapy of pulmonary arterial hypertension. European Respiratory Journal, 2019, 53, 1801889.	3.1	614
29	Updated Treatment Algorithm of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2013, 62, D60-D72.	1.2	596
30	Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. Journal of the American College of Cardiology, 2002, 39, 1496-1502.	1.2	584
31	Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. European Respiratory Journal, 2004, 24, 353-359.	3.1	574
32	Survival with first-line bosentan in patients with primary pulmonary hypertension. European Respiratory Journal, 2005, 25, 244-249.	3.1	565
33	Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension. Annals of Internal Medicine, 2008, 149, 521.	2.0	558
34	A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. European Heart Journal, 2008, 30, 394-403.	1.0	553
35	Pulmonary Hypertension Due to Left Heart Diseases. Journal of the American College of Cardiology, 2013, 62, D100-D108.	1.2	541
36	BMPR2 Haploinsufficiency as the Inherited Molecular Mechanism for Primary Pulmonary Hypertension. American Journal of Human Genetics, 2001, 68, 92-102.	2.6	521

#	Article	IF	Citations
37	Pulmonary Hypertension in Chronic Lung Diseases. Journal of the American College of Cardiology, 2013, 62, D109-D116.	1.2	518
38	Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension. Circulation, 2013, 127, 1128-1138.	1.6	482
39	Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S78-S84.	1.2	463
40	Treatment of Pulmonary Arterial Hypertension With the Selective Endothelin-A Receptor Antagonist Sitaxsentan. Journal of the American College of Cardiology, 2006, 47, 2049-2056.	1.2	462
41	Right heart thrombi in pulmonary embolism. Journal of the American College of Cardiology, 2003, 41, 2245-2251.	1.2	445
42	Ambrisentan Therapy for Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2005, 46, 529-535.	1.2	441
43	The endothelin system in pulmonary arterial hypertension. Cardiovascular Research, 2004, 61, 227-237.	1.8	412
44	Mutations of the TGF-Î² type II receptorBMPR2 in pulmonary arterial hypertension. Human Mutation, 2006, 27, 121-132.	1.1	368
45	An overview of the 6th World Symposium on Pulmonary Hypertension. European Respiratory Journal, 2019, 53, 1802148.	3.1	345
46	Effects of the oral endothelin-receptorantagonist bosentan on echocardiographicand doppler measures in patients with pulmonary arterial hypertension. Journal of the American College of Cardiology, 2003, 41, 1380-1386.	1.2	334
47	Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C) Tj ETQq1 1 0.784314 rgBT /Ov		
48	BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respiratory Medicine,the, 2016, 4, 129-137.	5.2	307
49	Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. European Respiratory Journal, 2006, 28, 1195-1203.	3.1	299
50	ERS statement on chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2021, 57, 2002828.	3.1	287
51	Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. European Respiratory Journal, 2012, 40, 874-880.	3.1	267
52	Impact of Thrombolytic Therapy onÂtheÂLong-Term Outcome of Intermediate-Risk PulmonaryÂEmbolism. Journal of the American College of Cardiology, 2017, 69, 1536-1544.	1.2	258
53	Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. European Heart Journal, 2014, 35, 716-724.	1.0	246
54	Long-term Treatment With Sildenafil Citrate in Pulmonary Arterial Hypertension. Chest, 2011, 140, 1274-1283.	0.4	237

#	Article	IF	Citations
55	Treprostinil, a Prostacyclin Analogue, in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. Chest, 2004, 126, 420-427.	0.4	232
56	Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, 1971-1981.	1.2	227
57	Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: Results of the BREATHE-5 open-label extension study. International Journal of Cardiology, 2008, 127, 27-32.	0.8	215
58	The role of the right ventricle in pulmonary arterial hypertension. European Respiratory Review, 2011, 20, 243-253.	3.0	210
59	End Points and Clinical Trial Design in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S97-S107.	1.2	209
60	Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. Journal of the American College of Cardiology, 2004, 43, S81-S88.	1.2	206
61	Stress Doppler Echocardiography in Relatives of Patients With Idiopathic and Familial Pulmonary Arterial Hypertension. Circulation, 2009, 119, 1747-1757.	1.6	205
62	Eisenmenger Syndrome. Journal of the American College of Cardiology, 2009, 53, 733-740.	1.2	199
63	BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Human Mutation, 2006, 27, 212-213.	1.1	196
64	Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax, 2005, 60, 1025-1030.	2.7	180
65	Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Research in Cardiology, 2005, 100, 131-138.	2.5	174
66	Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). European Respiratory Journal, 2015, 45, 1303-1313.	3.1	174
67	Pulmonary Microvascular Disease in Chronic Thromboembolic Pulmonary Hypertension. Proceedings of the American Thoracic Society, 2006, 3, 571-576.	3.5	172
68	Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities. Chest, 2009, 135, 122-129.	0.4	167
69	Vardenafil in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1723-1729.	2.5	162
70	Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. European Heart Journal, 2010, 31, 2080-2086.	1.0	157
71	Prognostic Implications of Serial Assessments of Pulmonary Hypertension in Severe Chronic Heart Failure. Journal of Heart and Lung Transplantation, 2006, 25, 1241-1246.	0.3	155
72	Management of Pulmonary Arterial Hypertension Associated with Congenital Systemic-to-Pulmonary Shunts and Eisenmenger???s Syndrome. Drugs, 2008, 68, 1049-1066.	4.9	153

#	Article	IF	Citations
73	Outcome after Cardiopulmonary Resuscitation in Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 341-344.	2.5	152
74	PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. European Respiratory Journal, 2015, 45, 1314-1322.	3.1	152
75	Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. Journal of Rheumatology, 2007, 34, 2417-22.	1.0	152
76	Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. Lancet Respiratory Medicine,the, 2020, 8, 873-884.	5.2	139
77	Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Annals of the Rheumatic Diseases, 2017, 76, 1219-1227.	0.5	135
78	Early detection of pulmonary vascular disease in pulmonary arterial hypertension: time to move forward. European Heart Journal, 2011, 32, 2489-2498.	1.0	132
79	New Treatments for Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1209-1216.	2.5	129
80	Tadalafil for the Treatment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2012, 60, 768-774.	1.2	124
81	Prostanoids for Pulmonary Arterial Hypertension. Treatments in Respiratory Medicine, 2003, 2, 123-137.	1.4	123
82	Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTUREâ€1 study. British Journal of Clinical Pharmacology, 2009, 68, 948-955.	1.1	105
83	Role of pharmacologic tests in the treatment of primary pulmonary hypertension. American Journal of Cardiology, 1995, 75, 55A-62A.	0.7	104
84	Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2015, 34, 1366-1375.	0.3	103
85	Sitaxsentan for the Treatment of Pulmonary Arterial Hypertension. Chest, 2008, 134, 775-782.	0.4	99
86	Diagnosis, Treatment, and Clinical Management of Pulmonary Arterial Hypertension in the Contemporary Era. JAMA Cardiology, 2016, 1, 1056.	3.0	99
87	Pulmonary arterial hypertension associated to connective tissue diseases. Lupus, 2005, 14, 713-717.	0.8	97
88	Treatment of pulmonary hypertension. Lancet Respiratory Medicine,the, 2016, 4, 323-336.	5.2	97
89	Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. European Respiratory Journal, 2017, 50, 1602493.	3.1	97
90	Pulmonary arterial capacitance in patients with heart failure and reactive pulmonary hypertension. European Journal of Heart Failure, 2015, 17, 74-80.	2.9	96

#	Article	IF	Citations
91	Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2011, 30, 632-643.	0.3	95
92	Left Main Coronary Artery Compression in Patients With Pulmonary Arterial Hypertension andÂAngina. Journal of the American College of Cardiology, 2017, 69, 2808-2817.	1.2	91
93	A Novel Alu-Like Element Rearranged in the Dystrophin Gene Causes a Splicing Mutation in a Family with X-Linked Dilated Cardiomyopathy. American Journal of Human Genetics, 1998, 63, 436-446.	2.6	90
94	Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary ArterialÂHypertension. Journal of the American College of Cardiology, 2021, 78, 1393-1403.	1.2	90
95	Primary Pulmonary Hypertension. Chest, 1998, 114, 184S-194S.	0.4	87
96	Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 <scp>ESC</scp>/<scp>ERS</scp> guidelines and insights for future changes. European Journal of Heart Failure, 2018, 20, 248-255.	2.9	85
97	Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further researchâ€. European Heart Journal, 2017, 38, ehw597.	1.0	83
98	Evaluation of Macitentan in Patients With Eisenmenger Syndrome. Circulation, 2019, 139, 51-63.	1.6	83
99	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. Journal of the American College of Cardiology, 2018, 71, 752-763.	1.2	82
100	The new clinical trials on pharmacological treatment in pulmonary arterial hypertension. European Respiratory Journal, 2002, 20, 1037-1049.	3.1	81
101	Rapid Switch From Intravenous Epoprostenol to Intravenous Treprostinil in Patients With Pulmonary Arterial Hypertension. Journal of Cardiovascular Pharmacology, 2007, 49, 1-5.	0.8	77
102	Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. American Journal of Cardiovascular Drugs, 2018, 18, 37-47.	1.0	69
103	Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. American Heart Journal, 2002, 143, 4A-10A.	1.2	68
104	Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. Circulation, 2019, 139, 2440-2450.	1.6	67
105	Hyperglycemia, inflammatory response and infarct size in obstructive acute myocardial infarction and MINOCA. Cardiovascular Diabetology, 2021, 20, 33.	2.7	66
106	SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. European Heart Journal, 2017, 38, 1147-1155.	1.0	65
107	Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: A subgroup analysis. International Journal of Cardiology, 2010, 144, 373-378.	0.8	64
108	Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. Journal of Heart and Lung Transplantation, 2019, 38, 1286-1295.	0.3	62

#	Article	IF	Citations
109	Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients. Frontiers in Pharmacology, 2020, 11, 1124.	1.6	61
110	Corrigendum to: 'Guidelines for the diagnosis and treatment of pulmonary hypertension' [European Heart Journal (2009) 30, 2493-2537]. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal, 2011, 32, 926-926.	1.0	60
111	Pulmonary hypertension in left heart disease. European Respiratory Review, 2012, 21, 338-346.	3.0	60
112	EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. American Heart Journal, 2014, 167, 210-217.	1.2	59
113	Acute Hemodynamic Effects of Singleâ€Dose Sildenafil When Added to Established Bosentan Therapy in Patients With Pulmonary Arterial Hypertension: Results of the COMPASSâ€1 Study. Journal of Clinical Pharmacology, 2009, 49, 1343-1352.	1.0	57
114	Pulmonary arterial hypertension associated with congenital heart disease: Recent advances and future directions. International Journal of Cardiology, 2014, 177, 340-347.	0.8	57
115	Use of Î²-Blockers in Pulmonary Hypertension. Circulation: Heart Failure, 2017, 10, .	1.6	56
116	MEDICAL THERAPY OF PULMONARY HYPERTENSION. Clinics in Chest Medicine, 2001, 22, 529-537.	0.8	54
117	The value of ECG changes in risk stratification of COVIDâ€19 patients. Annals of Noninvasive Electrocardiology, 2021, 26, e12815.	0.5	54
118	Liver toxicity of sitaxentan in pulmonary arterial hypertension. European Respiratory Journal, 2011, 37, 475-476.	3.1	53
119	Can â€œInoperableâ€•Congenital Heart Defects Become Operable in Patients with Pulmonary Arterial Hypertension? Dream or Reality?. Congenital Heart Disease, 2012, 7, 3-11.	0.0	53
120	Secondary Prevention Medical Therapy and Outcomes in Patients With Myocardial Infarction With Non-Obstructive Coronary Artery Disease. Frontiers in Pharmacology, 2019, 10, 1606.	1.6	53
121	End-points and clinical trial design in pulmonary arterial hypertension: have we made progress?. European Respiratory Journal, 2009, 34, 231-242.	3.1	51
122	Effect of Macitentan on Hospitalizations. JACC: Heart Failure, 2015, 3, 1-8.	1.9	51
123	Pulmonary Arterial Hypertension: Combination Therapy in Practice. American Journal of Cardiovascular Drugs, 2018, 18, 249-257.	1.0	51
124	Current and Future Management of Chronic Thromboembolic Pulmonary Hypertension: From Diagnosis to Treatment Responses. Proceedings of the American Thoracic Society, 2006, 3, 601-607.	3.5	48
125	Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. International Journal of Cardiology, 2014, 172, 332-339.	0.8	47
126	Macitentan Improves Health-Related QualityÂof Life for Patients With Pulmonary Arterial Hypertension. Chest, 2017, 151, 106-118.	0.4	46

#	Article	IF	Citations
127	Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights. European Respiratory Journal, 2015, 46, 414-421.	3.1	44
128	Incomplete echocardiographic recovery at 6Âmonths predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial. Clinical Research in Cardiology, 2019, 108, 772-778.	1.5	44
129	Impact of admission hyperglycemia on short and long-term prognosis in acute myocardial infarction: MINOCA versus MIOCA. Cardiovascular Diabetology, 2021, 20, 192.	2.7	44
130	Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals. European Respiratory Review, 2010, 19, 272-278.	3.0	43
131	The role of physical activity in individuals with cardiovascular risk factors: an opinion paper from Italian Society of Cardiology-Emilia Romagna-Marche and SIC-Sport. Journal of Cardiovascular Medicine, 2019, 20, 631-639.	0.6	43
132	Pulmonary artery intimal sarcoma. Problems in the differential diagnosis. Radiologia Medica, 2013, 118, 1259-1268.	4.7	42
133	Sodium butyrate inhibits plateletâ€derived growth factorâ€induced proliferation and migration in pulmonary artery smooth muscle cells through <scp>A</scp>kt inhibition. FEBS Journal, 2013, 280, 2042-2055.	2.2	41
134	Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. European Journal of Heart Failure, 2019, 21, 352-359.	2.9	40
135	Diagnostic Accuracy of Cardiac Computed Tomography and 18-F Fluorodeoxyglucose Positron Emission Tomography in Cardiac Masses. JACC: Cardiovascular Imaging, 2020, 13, 2400-2411.	2.3	40
136	Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. European Respiratory Journal, 2015, 46, 1711-1720.	3.1	39
137	Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. Journal of Heart and Lung Transplantation, 2020, 39, 300-309.	0.3	39
138	Emerging medical therapies for pulmonary arterial hypertension. Progress in Cardiovascular Diseases, 2002, 45, 213-224.	1.6	38
139	Evaluation of pulmonary arterial hypertension. Current Opinion in Cardiology, 2004, 19, 575-581.	0.8	38
140	New Treatment Strategies for Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2013, 62, 1101-1102.	1.2	38
141	FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion. International Journal of Cardiology, 2016, 202, 52-58.	0.8	37
142	New horizons in pulmonary arterial hypertension therapies. European Respiratory Review, 2013, 22, 503-514.	3.0	36
143	Limitation of Myocardial Infarct Size by Nicorandil After Sustained Ischemia in Pigs. Journal of Cardiovascular Pharmacology, 1995, 26, 477-484.	0.8	35
144	Impact of Admission Hyperglycemia on Heart Failure Events and Mortality in Patients With Takotsubo Syndrome at Long-term Follow-up: Data From HIGH-GLUCOTAKO Investigators. Diabetes Care, 2021, 44, 2158-2161.	4.3	35

#	Article	IF	Citations
145	Pulmonary arterial hypertension: a look to the future. Journal of the American College of Cardiology, 2004, 43, S89-S90.	1.2	34
146	Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed. European Respiratory Journal, 2010, 36, 986-990.	3.1	34
147	Do we need controlled clinical trials in pulmonary arterial hypertension?. European Respiratory Journal, 2001, 17, 1-3.	3.1	33
148	The use of combination therapy in pulmonary arterial hypertension: new developments. European Respiratory Review, 2009, 18, 148-153.	3.0	33
149	Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. PLoS ONE, 2018, 13, e0193226.	1.1	33
150	Clinical worsening in trials of pulmonary arterial hypertension: results and implications. Current Opinion in Pulmonary Medicine, 2010, 16, S11-S19.	1.2	31
151	Pulmonary endarterectomy: an alternative to circulatory arrest and deep hypothermia: mid-term results. European Journal of Cardio-thoracic Surgery, 2008, 34, 159-163.	0.6	29
152	Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings. Europace, 2020, 22, 1855-1863.	0.7	28
153	The REPAIR Study. JACC: Cardiovascular Imaging, 2022, 15, 240-253.	2.3	28
154	ARIES-1: A PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF AMBRISENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION. Chest, 2006, 130, 121S.	0.4	27
155	Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. Chest, 2020, 157, 955-965.	0.4	26
156	Estrategias terapÃ©uticas actuales en la hipertensiÃ³n arterial pulmonar. Revista Espanola De Cardiologia, 2010, 63, 708-724.	0.6	24
157	Dissecting histone deacetylase role in pulmonary arterial smooth muscle cell proliferation and migration. Biochemical Pharmacology, 2014, 91, 181-190.	2.0	24
158	A Combined Targeted and Whole Exome Sequencing Approach Identified Novel Candidate Genes Involved in Heritable Pulmonary Arterial Hypertension. Scientific Reports, 2019, 9, 753.	1.6	24
159	Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2014, 33, 689-697.	0.3	23
160	Pulmonary veno-occlusive disease: the role of CT. Radiologia Medica, 2014, 119, 667-673.	4.7	23
161	Pulmonary hypertension in primary SjÃ¶grenâ€™s syndrome: report of a case and review of the literature. Clinical Rheumatology, 2005, 24, 431-434.	1.0	22
162	Pulmonary arterial hypertension in the pediatric age. Journal of Cardiovascular Medicine, 2007, 8, 72-77.	0.6	22

#	Article	IF	Citations
163	Comparison of hemodynamic parameters in treatment-naÃ¯ve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. Journal of Heart and Lung Transplantation, 2017, 36, 509-519.	0.3	22
164	The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the <scp>GRIPHON</scp> study. European Journal of Heart Failure, 2022, 24, 205-214.	2.9	22
165	Usefulness of nicorandil in congestive heart failure. American Journal of Cardiology, 1990, 65, 343-348.	0.7	21
166	Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension. Chest, 2021, 160, 277-286.	0.4	21
167	Predictive value of M-mode echocardiography in patients with congestive heart failure. American Heart Journal, 1986, 111, 697-702.	1.2	20
168	Initial combination therapy with ambrisentanâ€¯+â€¯tadalafil on pulmonary arterial hypertensionâ€'related hospitalization in the AMBITION trial. Journal of Heart and Lung Transplantation, 2019, 38, 194-202.	0.3	19
169	Prevalence and Incidence of Atrial Fibrillation in a Large Cohort of Adrenal Incidentalomas: A Long-Term Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2770-e2777.	1.8	19
170	Exercise training in pulmonary hypertension: improving performance but waiting for outcome. European Heart Journal, 2016, 37, 45-48.	1.0	18
171	Effect of enoximone alone and in combination with metoprolol on myocardial function and energetics in severe congestive heart failure: Improvement in hemodynamic and metabolic profile. Cardiovascular Drugs and Therapy, 1993, 7, 337-347.	1.3	17
172	Future perspectives in pulmonary arterial hypertension. European Respiratory Review, 2016, 25, 381-389.	3.0	17
173	Liver toxicity of sitaxentan in pulmonary arterial hypertension. European Heart Journal, 2011, 32, 386-7.	1.0	16
174	Pharmacological impact on right ventricular remodelling in pulmonary arterial hypertension. Country Review Ukraine, 2007, 9, H68-H74.	0.8	15
175	CardioPulse Articles. European Heart Journal, 2011, 32, 385-392.	1.0	15
176	The study of risk in pulmonary arterial hypertension. European Respiratory Review, 2012, 21, 234-238.	3.0	15
177	Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI 2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. Journal of Heart and Lung Transplantation, 2018, 37, 401-408.	0.3	15
178	Application of a new pulmonary artery obstruction score in the prognostic evaluation of acute pulmonary embolism: comparison with clinical and haemodynamic parameters. Radiologia Medica, 2011, 116, 230-245.	4.7	14
179	Letter by Hoeper and GaliÃ¨ Regarding Article, â€œHemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension of Different Causes: Phase II Results From the Pulmonary Artery Denervation-1 Studyâ€• Circulation: Cardiovascular Interventions, 2016, 9, e003422.	1.4	14
180	Pulmonary endarterectomy: is there an alternative to profound hypothermia with cardiocirculatory arrest?. European Journal of Cardio-thoracic Surgery, 2006, 30, 563-565.	0.6	13

#	Article	IF	Citations
181	Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study. Journal of Heart and Lung Transplantation, 2017, 36, 399-406.	0.3	13
182	Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease. International Journal of Cardiology, 2017, 235, 67-72.	0.8	13
183	Pulmonary arterial hypertension: bridging the present to the future. European Respiratory Review, 2012, 21, 267-270.	3.0	12
184	Extensive right pulmonary artery dissection in a young patient with chronic pulmonary hypertension. Heart, 2012, 98, 265-266.	1.2	12
185	Vasoactive Intestinal Peptide in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 786-786.	2.5	12
186	Pulmonary hypertension and systemic sclerosis: the role of high-resolution computed tomography. Radiologia Medica, 2013, 118, 1360-1372.	4.7	12
187	Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. Advances in Therapy, 2022, 39, 796-810.	1.3	12
188	Pediatric Restrictive Cardiomyopathies. Frontiers in Pediatrics, 2021, 9, 745365.	0.9	12
189	Densitometric CT evaluation of acute and chronic thromboembolic filling defects of the pulmonary arteries before and after contrast injection. Radiologia Medica, 2012, 117, 979-991.	4.7	11
190	Evaluation of mosaic pattern areas in HRCT with Min-IP reconstructions in patients with pulmonary hypertension: Could this evaluation replace lung perfusion scintigraphy?. European Journal of Radiology, 2012, 81, e1-e6.	1.2	11
191	Aiming at the appropriate target for the treatment of pulmonary hypertension due to left heart disease. European Heart Journal, 2018, 39, 1265-1268.	1.0	11
192	Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial. Lancet Haematology,the, 2021, 8, e627-e636.	2.2	11
193	Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the Phase III PATENT-1 study. Journal of Heart and Lung Transplantation, 2015, 34, 338-347.	0.3	10
194	The difficult diagnosis of pulmonary vascular disease in heart failure. European Respiratory Journal, 2016, 48, 311-314.	3.1	10
195	Clues and pitfalls in the diagnostic approach to cardiac masses: are pseudo-tumours truly benign?. European Journal of Preventive Cardiology, 2022, 29, e102-e104.	0.8	10
196	Lung neovascularity in pulmonary arterial hypertension associated with congenital heart defects and idiopathic pulmonary arterial hypertension: study of 198 patients. European Radiology, 2012, 22, 1059-1066.	2.3	9
197	Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study. Thrombosis and Haemostasis, 2017, 117, 2425-2434.	1.8	9
198	Developing a Heart Score: Next Steps. American Journal of Cardiology, 2012, 110, S49-S51.	0.7	8

#	Article	IF	Citations
199	Occurring ofIn VitroFunctional Vasculogenic Pericytes from Human Circulating Early Endothelial Precursor Cell Culture. Stem Cells International, 2015, 2015, 1-11.	1.2	8
200	Bronchial artery embolization for the treatment of haemoptysis in pulmonary hypertension. Radiologia Medica, 2017, 122, 257-264.	4.7	8
201	Acute hand ischemia after radial intervention in patient with CREST-associated pulmonary hypertension: successful treatment with manual thromboaspiration. Journal of Invasive Cardiology, 2013, 25, 89-91.	0.4	8
202	Bosentan for Pulmonary Hypertension. New England Journal of Medicine, 2002, 347, 292-294.	13.9	7
203	Association of the European Society of Cardiology echocardiographic probability grading for pulmonary hypertension with short and mid-term clinical outcomes after heart valve surgery. Vascular Pharmacology, 2020, 125-126, 106648.	1.0	7
204	Pattern of arterial inflammation and inflammatory markers in people living with HIV compared with uninfected people. Journal of Nuclear Cardiology, 2022, 29, 1566-1575.	1.4	7
205	Rare causes of pulmonary hypertension: spectrum of radiological findings and review of the literature. Radiologia Medica, 2014, 119, 41-53.	4.7	6
206	Thoracic Manifestation of Eisenmengerâ€™s Syndrome in Adult Patients: A MDCT Review. Lung, 2015, 193, 173-181.	1.4	6
207	Improving patient outcomes in pulmonary hypertension. European Respiratory Review, 2015, 24, 550-551.	3.0	5
208	Extracorporeal cardiopulmonary support in acute high-risk pulmonary embolism: still waiting for solid evidence. European Heart Journal, 2018, 39, 4205-4207.	1.0	5
209	Thrombolysis in high-risk patients with acute pulmonary embolism: underuse of a life-saving treatment in the real-world setting. European Heart Journal, 2020, 41, 530-533.	1.0	5
210	Transcatheter aortic valve implantation for severe autograft regurgitation after Ross operation. EuroIntervention, 2014, 10, 141-145.	1.4	5
211	Cardiovascular Diseases That Have Emerged From the Darkness. Journal of the American Heart Association, 2021, 10, e021095.	1.6	5
212	Current Therapeutic Approaches to Pulmonary Arterial Hypertension. Revista Espanola De Cardiologia (English Ed), 2010, 63, 708-724.	0.4	4
213	Anticoagulant treatment in patients with pulmonary arterial hypertension associated with systemic sclerosis: More shadows than lights. Journal of Scleroderma and Related Disorders, 2018, 3, 39-42.	1.0	4
214	Eisenmenger syndrome and pulmonary arterial hypertension in adults with congenital heart disease. Current Medical Research and Opinion, 2007, 23, S19-S25.	0.9	3
215	A paradigm shift in pulmonary arterial hypertension management. European Respiratory Review, 2013, 22, 423-426.	3.0	3
216	New horizons in pulmonary arterial hypertension management. European Respiratory Review, 2014, 23, 408-409.	3.0	3

#	Article	IF	Citations
217	Letter by Suissa and GaliÃ© Regarding Article, â€œAnticoagulation and Survival in Pulmonary Arterial Hypertension: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)â€. Circulation, 2014, 130, e107.	1.6	3
218	Primary malignant pericardial tumour in Lynch syndrome. BMC Cancer, 2020, 20, 191.	1.1	3
219	Donorâ€derived human herpesvirus 8 infection with Kaposi sarcoma and Kaposi sarcoma inflammatory cytokine syndrome in a heart transplant recipient: A case report. Transplant Infectious Disease, 2021, 23, e13609.	0.7	3
220	A pragmatic approach to risk assessment in pulmonary arterial hypertension using the 2015 European Society of Cardiology/European Respiratory Society guidelines. Open Heart, 2021, 8, e001725.	0.9	3
221	Preoperative checklist to reduce the risk of cardiac implantable electronic device infections. PACE - Pacing and Clinical Electrophysiology, 2022, 45, 262-269.	0.5	3
222	Case report: Congenital extrahepatic portocaval shunt presenting as pulmonary arterial hypertension in a pregnant patient. Pulmonary Circulation, 2022, 12, e12008.	0.8	3
223	Pulmonary arterial hypertension: therapeutic algorithm. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2005, 6, 856-60.	0.1	3
224	Phosphodiesterase inhibitors for pulmonary hypertension. New England Journal of Medicine, 2010, 362, 559-60; author reply 560.	13.9	3
225	Therapeutic alternatives in chronic thromboembolic pulmonary hypertension: from pulmonary endarterectomy to balloon pulmonary angioplasty to medical therapy. State of the art from a multidisciplinary team. Annals of Cardiothoracic Surgery, 2022, 11, 120-127.	0.6	3
226	Indoramin in heart failure: Possible adverse effects on hemodynamics and exercise capacity. Clinical Pharmacology and Therapeutics, 1986, 40, 567-574.	2.3	2
227	Use of Multiple-Action Agents on the Heart. Journal of Cardiovascular Pharmacology, 1992, 19, S44-S49.	0.8	2
228	Left ventricular dimensions in pulmonary arterial hypertension: haemodynamic and exercise correlations. Current Medical Research and Opinion, 2007, 23, S55-S62.	0.9	2
229	GuÃa de prÃ¡ctica clÃnica para el diagnÃ³stico y tratamiento de la hipertensiÃ³n pulmonar. Revista Espanola De Cardiologia (English Ed), 2009, 62, 1464.e1-1464.e58.	0.4	2
230	Percutaneous Mitral Valve Repair with the MitraClip System in the Current Clinical Practice. Hearts, 2021, 2, 74-86.	0.4	2
231	Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension. Advances in Therapy, 2022, 39, 4374-4390.	1.3	2
232	Myocardial, coronary, and peripheral effects of xamoterol (ICI 118,587) in open-chest pigs. Cardiovascular Drugs and Therapy, 1989, 3, 91-97.	1.3	1
233	Inhaled Iloprost. Drugs, 2004, 64, 774-775.	4.9	1
234	GPs Meet Rare Lung Disorders Task Force factsheet: pulmonary arterial hypertension. Breathe, 2015, 11, 233-236.	0.6	1

#	Article	IF	Citations
235	Beyond the World Symposium on Pulmonary Hypertension: practical management of pulmonary arterial hypertension and evolving concepts. European Heart Journal Supplements, 2019, 21, K1-K3.	0.0	1
236	Subacute pericardial abscess after aortic valve replacement: a case report. BMC Infectious Diseases, 2020, 20, 342.	1.3	1
237	Cum Grano Salis: Cardiac Sarcoidosis as a Perfect Mimic of Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation: Cardiovascular Imaging, 2021, 14, e012355.	1.3	1
238	CORRELATION OF WHO FUNCTIONAL CLASS AND INDICES OF DISEASE SEVERITY IN IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION: INSIGHTS FROM EARLY, BREATHE-1 AND 351 STUDIES. Chest, 2006, 130, 254S.	0.4	1
239	Response to Comment on Paolisso et al. Impact of Admission Hyperglycemia on Heart Failure Events and Mortality in Patients With Takotsubo Syndrome at Long-term Follow-up: Data From HIGH-GLUCOTAKO Investigators. Diabetes Care 2021;44:2158â€“2161. Diabetes Care, 2021, 44, e201-e202.	4.3	1
240	Long-term therapeutic outcomes in pulmonary arterial hypertension. Current Medical Research and Opinion, 2007, 23, S11-S18.	0.9	0
241	Evidence for Kaposi's sarcoma-associated herpes virus infection in patients with idiopathic pulmonary arterial hypertension: a case series and review of the literature. Current Medical Research and Opinion, 2007, 23, S83-S87.	0.9	0
242	Bosentan in mild pulmonary hypertension â€“ Authors' reply. Lancet, The, 2008, 372, 1731-1732.	6.3	0
243	Pulmonary Hypertension and Left Heart Disease. Progress in Respiratory Research, 2012, , 161-168.	0.1	0
244	RecomendaÃ§Ãµes da ESC para o tratamento da cardiopatia congÃ©nita no adulto (nova versÃ£o de 2010). Revista Portuguesa De Cardiologia, 2012, 31, 541.e1-541.e53.	0.2	0
245	Respiratory therapy for airway inflammation in patients with Eisenmenger syndrome. International Journal of Therapy and Rehabilitation, 2017, 24, 372-372.	0.1	0
246	HipertensiÃ³n pulmonar tromboembÃ³lica crÃ³nica: caracterizaciÃ³n, endarterectomÃa pulmonar y nuevas opciones terapÃ©uticas. Cirugia Cardiovascular, 2018, 25, 93-101.	0.1	0
247	Pulmonary vascular disease due to left heart disease: how to achieve a more accurate approach beyond the haemodynamic phenotype: reply. European Journal of Heart Failure, 2018, 20, 943-943.	2.9	0
248	Cost-effectiveness of cardiac resynchronization therapy. Journal of Medical Economics, 2020, 23, 1375-1378.	1.0	0
249	A Historical Perspective of Cardiac Implantable Electronic Device Infection: How a Menace Can Drive Technological and Clinical Improvement. Hearts, 2021, 2, 202-212.	0.4	0
250	Report From the Task Force on Medical Treatments. Advances in Pulmonary Hypertension, 2003, 2, 16-16.	0.1	0
251	Pulmonary Arterial Hypertension: Where Are We and Where Are We Going?. Advances in Pulmonary Hypertension, 2009, 8, 102-102.	0.1	0
252	Conventional medical therapies. , 2011, , 303-312.		0

#	Article	IF	Citations
253	Current medical therapies in pulmonary arterial hypertension. , 2012, , 26-41.		0
254	A Treatment Algorithm for Pulmonary Arterial Hypertension. Advances in Pulmonary Hypertension, 2014, 13, 31-37.	0.1	0
255	Comparative Analysis of Clinical Trials and Evidence-Based Treatment Algorithm for Pulmonary Arterial Hypertension. , 0, , 203-221.		0